Stepronin
(Synonyms: Prostenoglycine; TTPG; Tiase) 目录号 : GC68477Stepronin (Prostenoglycine) 是一种口服有效的祛痰剂 (吸入给药优于口服给药)。Stepronin 在体外通过减少上皮细胞的 Cl- 分泌和粘膜下腺体的粘液糖蛋白分泌来抑制气道分泌。
Cas No.:72324-18-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Stepronin (Prostenoglycine) is an orally active expectorant (inhalation administration is preferable to oral administration). Stepronin inhibits airway secretion in vitro by reducing Cl- secretion from epithelial cells and mucus glycoprotein secretion from submucosal glands[1].
Stepronin (0.1-100 µM; 20 min) induces significant reductions in ISOP(Isoproterenol)-evoked SCC (short circuit current) value in a dose-dependent manner in canine tracheal epithelium[1].
Stepronin (10-100 µM; 20 min) significantly inhibits the basal secretion and ISOP-evoked PD (potential difference) value in a dose-dependent manner in canine tracheal epithelium[1].
Stepronin (100 µM; 20 min) significantly inhibits ISOP-induced [3H]-glycoconjugate secretion in submucosal glands[1].
Cell Viability Assay[1]
| Cell Line: | Canine tracheal epithelium (from adult and 10 to 25 kg-weight mongrel dogs of both sexes) |
| Concentration: | 0.1-100 µM; 10-100 µM |
| Incubation Time: | 20 min (pre-treat) |
| Result: | Significantly inhibited ISOP-induced SCC and PD values, as well as basal secretion. |
Cell Viability Assay[1]
| Cell Line: | Submucosal glands (from adult and 10 to 25 kg-weight mongrel dogs of both sexes) |
| Concentration: | 100 µM |
| Incubation Time: | 20 min (pre-treat) |
| Result: | Significantly inhibited ISOP- induced [3H]-glycoconjugate secretion. |
[1]. Yamada K, et al. An expectorant, stepronin, reduces airway secretion in vitro. Respiration. 1994;61(1):42-7.
| Cas No. | 72324-18-6 | SDF | Download SDF |
| 别名 | Prostenoglycine; TTPG; Tiase | ||
| 分子式 | C10H11NO4S2 | 分子量 | 273.33 |
| 溶解度 | DMSO : ≥ 250 mg/mL (914.65 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.6586 mL | 18.2929 mL | 36.5858 mL |
| 5 mM | 0.7317 mL | 3.6586 mL | 7.3172 mL |
| 10 mM | 0.3659 mL | 1.8293 mL | 3.6586 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
An expectorant, Stepronin, reduces airway secretion in vitro
Respiration 1994;61(1):42-7.PMID:8177972DOI:10.1159/000196302.
Stepronin (SPN) is clinically used as an expectorant, and thenoic acid (TA) is its metabolite. We examined the effects of these drugs on the bioelectric parameters [potential difference (PD), short circuit current (SCC), conductance (G)] of the posterior epithelial membrane of canine trachea and on those of the mucus glycoprotein secretion from feline tracheal isolated glands. PD and SCC were obtained using an Ussing chamber and G was calculated as the ratio SCC/PD. Neither SPN nor TA significantly altered the baseline values of PD and SCC. However, in the mucosal solution, both SPN and TA significantly inhibited PD and SCC evoked by isoproterenol (ISOP), whereas G remained unchanged. Amirolide did not alter the inhibitory action of SPN and TA. Mucus glycoprotein secretion from isolated glands was estimated by measuring trichloride acetic acid-precipitable [3H]-glycoconjugates. SPN and TA significantly reduced mucus glycoprotein secretion. Further, when stimulated by methacholine, these agents significantly inhibited mucus glycoprotein secretion from isolated glands. These findings suggest that SPN inhibits airway secretion in vitro by both decreasing Cl- secretion from epithelial cells and mucus glycoprotein secretion from submucosal glands.
Accelerated cell-mediated broncho-obstructive reaction to inhaled Stepronin: a case report
Allergy 1996 Apr;51(4):269-71.PMID:8792926DOI:10.1111/j.1398-9995.1996.tb04605.x.
We describe the case of a 20-year-old man who developed an obstructive bronchial reaction accompanied by a maculopapular facial rash 8 h after an aerosol treatment with the mucolytic drug Stepronin. The results of intradermal and patch testing with Stepronin, together with those of bronchial challenge and histologic findings in patch-tested skin, indicate that the patient's reaction involved an accelerated cell-mediated mechanism of hypersensitivity. Bronchial challenges with methacholine demonstrated a transient increase in nonspecific bronchial hyperreactivity.
[A controlled clinical study on the efficacy and tolerability of Stepronin in chronic alcoholic liver diseases]
Clin Ter 1990 Nov 15;135(3):209-13.PMID:2150022doi
A group of 15 hospitalized chronic alcoholics was treated for 30 days with twice daily doses of 840 mg Stepronin and was compared to 15 patients receiving placebo. The favorable results of this treatment are reported together with statistically significant changes of laboratory tests.
[The therapeutic activity of Stepronin in viral hepatitis]
Minerva Med 1982 Oct 27;73(41):2897-904.PMID:6752758doi
The therapeutic effect of Stepronin in 5% glucosate solution has been evaluated in 55/110 viral hepatitis cases (10/55 of A type, 37/55 of B type and 8/55 of nA type nB type), versus other cases (8/55 of A type, 40/55 of B type of 7/55 of nA nB type), treated with 5% glucose solution only. In 18/110 viral hepatitis case of A type, final results with the two different therapies have not shown statistically significantly changes and were comparable. Particularly favourable, in the patients treated, the results obtained in viral hepatitis of B type and nA nB type, were very significant statistically at the end of therapy. In particular, the 2 transaminasic activities had a beneficial influence. Tolerance was very good: only in there cases nettlerash was observed and therapy interrupted in one patient. Therefore the validity of this sulphydryl pro-drug in the treatment of acute viral hepatitis of B and nA and nB type is confirmed.